Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2014, Vol. 34 Issue (1): 64-70    DOI: 10.13523/j.cb.20140110
    
Construction and Immune Efficacy of Recombinant Adenovirus Expressing H Gene of Canine Distemper Virus
YUAN Ying-shuo1,2, SONG Fei-fei1,2, LIU Guo-qiang1,2, LIU Ye2, ZHANG Shou-feng2, ZHANG Le-cui1, HU Rong-liang2
1. Qingdao Agriculture University, College of Animal Science and Technology, Qingdao 266109, China;
2. Jilin Provincial Key Laboratory of Zoonosis Prevention and Control, and Military Veterinary Research Institute, Academy of Military Medical Sciences, Changchun 130122, China
Download: HTML   PDF(1109KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  The recombinant human adenovirus type 5 that expressed hemagglutinin(H) protein gene of canine distemper virus(CDV) be constructed. The shuttle and backbone plasmid were respectively constructed by reverse transcription polymerase chain reaction (RT-PCR) and the restriction enzyme digestion and ligation, then co-transfected into the 293AD cell lines after Pac I linearization respectively. The biological characterization was determined by the electron microscope and restriction enzyme digestion and western blotting analysis and the one-step growth curve, the results proved that the recombinant human adenovirus type 5 that expressed H gene of CDV was constructed correctly. The anti-CDV antibody titers of the dog serum were detected by using neutralization test after a single intramuscular immunization with CDV vaccine strains or recombinants on days 14, 28, 42, 56, 70, 84. The results showed that average anti-CDV antibody titers (up to 2-8) were higher than that of the control group. It implied that the recombinant was constructed correctly and has a good immunogenicity, and it could stimulate an effective level of neutralizing antibodies which reached the lowest level of immune protection against CDV. This work provides a theoretical basis for the research and development of a more efficient distemper live vector vaccine.

Key wordsCanine distemper virus      Hemagglutinin gene      Adenovirus      Immune efficacy     
Received: 25 March 2013      Published: 25 January 2014
ZTFLH:  Q939.4  
Cite this article:

YUAN Ying-shuo, SONG Fei-fei, LIU Guo-qiang, LIU Ye, ZHANG Shou-feng, ZHANG Le-cui, HU Rong-liang. Construction and Immune Efficacy of Recombinant Adenovirus Expressing H Gene of Canine Distemper Virus. China Biotechnology, 2014, 34(1): 64-70.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20140110     OR     https://manu60.magtech.com.cn/biotech/Y2014/V34/I1/64

[1] Appel M J G, Summers B A. Pathogenicity of morbilliviruses for terrestrial carnivores. Vet Microbiol, 1995, 44:187-191.
[2] Silin D, Lyubomska O, Ludlow M, et al. Development of a challenge-protective vaccine concept by modification of the viral RNA-dependent RNA polymerase of canine distemper virus. J Virol, 2007, 81 (24):13649-13658.
[3] Kommonen C, Rudback E, Anttila M, et al. Canine distemper of vaccine origin in European mink, Mustela lutreola-a case report. Vet Microbiol, 2003, 92: 289-293.
[4] Fauquet C M, Mayo M A, Maniloff J, et al. Virus Taxonomy: VⅢth Report of the International Committee on Taxonomy of Viruses. San Diego: Elsevier Academic Press, 2005.
[5] Iwatsuki K, Tokiyoshis S, Hiaryame N, et al. Antigenic differences in the H proteins of canine distemper viruses. Vet Microbiol, 2000, 71: 281-286.
[6] Jensen T H, Nielsen L, Aasted B, et al. Early life DNA vaccination with the H gene of Canine distemper virus induces robust protection against distemper.Vaccine, 2009, 27(38):5178-5183.
[7] Hirama K, Togashi K, Vakasa C, et al. Cytotoxic T-lymphocyte activity specific for Hemgaglutinin (H) protein of canine distemper virus in dogs.Vet Med Sci, 2003, 65 (l):109-112.
[8] Nia T, Hildegund CJE. Adenoviruses as vaccine vectors. Molecular Therapy, 2004, 10(4):616-629.
[9] 殷震, 刘景华.动物病毒学.第2版.北京:科学技术出版社, 1997.736-767. Yin Z, Liu J H. Animal Virology. 2nd edition. Beijing: Science and Technology Press, 1997.736-767.
[10] Barrett T. Morbillivirus infections, with special emphasis on morbilliviruses of carnivores. Vet Microbiol, 1999, 69(1-2):3-13.
[11] von Messling V, Springfeld C, Devaux P, et al. A ferret model of canine distemper virus virulence and immunosuppression. J Virol, 2003, 77(23):12579-12591.
[12] Appel MJG. Canine distemper: Emerging new problems. Infect Dis Bull, 1996, 1:6.
[13] von Messling V, Zimmer G, Herrler G, et al. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol, 2001, 75 (14): 6418-6427.
[14] Sixt N, Cardoso A, Vallier A, et al. Narhalie S. Canine distemper virus DNA vaccination induces humoral and cellular immumity and protects against a lethal intracerebral challenge. Virology, 1998, 8472-8476.
[15] Charles R P. Distemper vaccination of dogs: factors which could cause vaccine failure. Can Vet J, 1986, 27:321-323.
[1] HUANG Lei,WAN Chang-qing,LIU Mei-qin,ZHAO Min,ZHENG Yan-peng,PENG Xiang-lei,YU Jie-mei,FU Yuan-hui,HE Jin-sheng. Construction of Recombinant Adenovirus Vectors Using the DNA Assembly Method[J]. China Biotechnology, 2021, 41(6): 23-26.
[2] ZHOU Yan, WANG Xiao-nan, YAN Shan-shan, WU Jin-yuan, SUN Mao-sheng, ZHANG Lei, LI Hong-jun. Construction and Coexpression of Recombinant Adenovirus Containing EGFP and Lmx1A[J]. China Biotechnology, 2014, 34(9): 72-79.
[3] HUANG Chen, WANG Jia-rong, YANG Ji-cheng, SHENG Wei-hua, MIAO Jing-cheng. The Inhibition of Ad. RGD-ING4-PTEN on MEG01 Human Leukemia Cell[J]. China Biotechnology, 2014, 34(3): 9-17.
[4] ZHOU Nian, HU Ning, GONG Xuan, WANG Chang-dong, LIAO Jun-yi, LIANG Xi, HUANG Wei. Construction and Identification of Recombinant Adenovirus Ad-HIF1α[J]. China Biotechnology, 2014, 34(3): 34-40.
[5] XIE Li, WANG Xiao-nan, LI Yang, YAN Min, CAO Yin, LI Hong-jun, SUN Mao-sheng. Construction and Immunogenicity of a Recombinant Adenovirus Expressing NSP4 of Group A Rotavirus[J]. China Biotechnology, 2014, 34(2): 1-6.
[6] MA Bu-yun, HE Wan-wan, ZHOU Li, WANG Yi-gang. The Study on Anticancer Effect of Targeting Gene-Virus ZD55-XAF1 in Liver Cancer Xenograft of Mice and Its Safety[J]. China Biotechnology, 2014, 34(1): 15-20.
[7] ZHANG Wen-feng, ZHANG Qiong-yu, BO Hua-ben, SHAO Hong-wei, LI Xiao-cheng, WANG Teng, HUANG Shu-lin. Prokaryotic Expression and Activity Detection of Ad5/Ad35 Fiber Gene[J]. China Biotechnology, 2013, 33(12): 15-20.
[8] ZHOU Li, HE Wan-wan, ZHU Zhen-nan, YANG Yuan-qin, ZHAO Hong-fang, MA Bu-yun, WANG Yi-gang. The Clinical Research Progress for Oncolytic Adenovirus Targeting Cancer Therapy[J]. China Biotechnology, 2013, 33(12): 105-113.
[9] MA Zhong-rui, HAN Dong-lei, ZHAO Jun-fei, CHEN Meng-lin, CHEN Min. Recent Developments in N-linked Glycoproteins Production in Escherichia coli and Glycoprotein Vaccines[J]. China Biotechnology, 2013, 33(11): 92-98.
[10] WANG Wan-pu, SUN Mao-sheng, LI Hong-jun, XIE Tian-hong, YAN Min, ZHOU Yan, YIN Na. Establishment of Bone Marrow Mesenchymal Stem Cells Expressing Neurotrophic Factor Neurturin and Activity Detection in Vitro[J]. China Biotechnology, 2012, 32(03): 1-6.
[11] ZHANG Feng-juan, YANG Ji-cheng, SHENG Wei-hua, WANG Jia-rong, MIAO Jing-cheng. The Growth-inhibitory Effect of Recombinant OSM-Adenovirus on A375 Melanoma Cells[J]. China Biotechnology, 2011, 31(11): 24-30.
[12] LIU Tie-lian, CHEN You-ming, HUANG Jing, LI Hua, YANG Ji-cheng. Construction of Adenovirus-mediated Ang1 and VEGF165 Co-expression Adenovirus Vector and Its Proangiogenesic Activity[J]. China Biotechnology, 2011, 31(11): 51-57.
[13] WEI Lin, QIU Fei, DIAO Yong. Macromolecule Modified Adenovirus as Vector for Gene Therapy[J]. China Biotechnology, 2011, 31(06): 111-115.
[14] QIAO Wei, HE Jin-shen, FU Yuan-hui, HONG Tao. The Characterization of Modified Adenovirus Vector[J]. China Biotechnology, 2011, 31(06): 86-92.
[15] GU Yuan-xing, WANG Meng, LIU Wen-qian, ZHANG Jie, LIU Yong-sheng. The Application Prospects of Ovine Adenovirus287 Vector[J]. China Biotechnology, 2011, 31(03): 101-106.